Aprepitant: all 129 studies that test it
Page 2 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells HarvestingStatus unknownNCT01088022Phase 3
- Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid CancerStatus unknownNCT01046461Phase 2
- Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian CancerWithdrawnNCT01017809Not applicable
- Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal RadiotherapyCompletedNCT00970905Phase 2
- Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric PatientsCompletedNCT00956215Not applicable
- Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer PatientsTerminatedNCT00869973Phase 3
- Aprepitant in the Prevention of Cisplatin-induced Delayed EmesisTerminatedNCT00869310Phase 3
- Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery PatientsCompletedNCT00738621Phase 4
- Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate AbusersStatus unknownNCT00726960Phase 1
- Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast CancerCompletedNCT00719173Phase 1
- Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and VomitingWithdrawnNCT00699894Not applicable
- Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer PatientsTerminatedNCT00588835Phase 4
- Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose ChemotherapyStatus unknownNCT00571168Phase 3
- Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With CancerWithdrawnNCT00499668Not applicable
- Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)WithdrawnNCT00429754Phase 4
- Effects of Treatment With Aprepitant (Emend®) in HIV Infected IndividualsCompletedNCT00428519Phase 1
- AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic ProgenitorsCompletedNCT00415103Phase 4
- Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell TransplantationCompletedNCT00314743Early Phase 1
- ONO-7436 Phase II Study in JapanCompletedNCT00212602Phase 2
- Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)CompletedNCT00080444Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)CompletedNCT00048607Phase 3
- Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)CompletedNCT00048594Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)CompletedNCT00042029Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)CompletedNCT00035295Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)CompletedNCT00035282Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)CompletedNCT00035048Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)CompletedNCT00035009Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)CompletedNCT00034983Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)CompletedNCT00034944Phase 3